[Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].

Objective: To verify applicability of the International Staging System (ISS) for multiple myeloma (MM) to 112 Chinese MM patients and compare ISS with Durie-Salmon (DS) and Intergroup Francophone du Myeloma (IFM) staging system in predicting prognosis.

Methods: 112 previously untreated MM patients in Blood Diseases Hospital of CAMS were analyzed according to ISS retrospectively.

Results: 1) Serum beta2-microglobulin (beta2-MG) > or = 3.

[Effects of beta-catenin-specific siRNA interference on Jurkat and K562 cells].

Objective: To inhibit the expression of beta-catenin and investigate the effect of the beta-catenin gene on Jurkat and K562 cells.

Methods: siRNA specifically knocking down the expression of beta-catenin was used to testify the function of beta-catenin in Jurkat and K562 cells. Real time polymerase chain reaction and Western blot were performed respectively to testify the mRNA level and protein level of beta-catenin.

[The expression of beta-catenin and its significance in leukemia cells].

Objective: To investigate the expression of beta-catenin in patients with leukemia and explore its significance in leukemias.

Methods: RT-PCR was used to detect the expression of beta-catenin in bone marrow mononuclear cells (BMMNCs) from patients with leukemia. Immunocytochemistry was in some of patients to detect the distribution of beta-catenin at the same time.

[Expression of beta-Catenin Gene in CML and its relationship with bcr/abl].

This study was aimed to quantitatively detect the expression level of beta-catenin and bcr/abl in different phases of chronic myeloid leukemia (CML) and to analyze their potential relationship and significance in the progression of CML. First, the total RNA isolated from BMMNC of patients with CML and donors was reversely transcribed into cDNA. The real-time quantitative PCR method was used to analyze the expression level of beta-catenin and bcr/abl.

[Expression of beta-Catenin in Leukemic Cell Lines].

This study was aimed to investigate the expression of beta-catenin in leukemic cell lines and its relationship with pathogenesis of leukemia, semi-quantitative RT-PCR and Western blot were performed to detect the expression of beta-catenin in a panel of 15 human hematopoietic cell lines (U937, KG1a, Jurkat, K562, Namalwa, HEL, HUT78, Raji, Daudi, CEM, LCL-H, HL-60, NB4, J6-1, Ramos). Immunocytochemistry was performed in some of these cell lines to detect the location of beta-catenin. The results showed that the beta-catenin gene was widely expressed in most leukemic cell lines in various degree, the high expression of beta-catenin was found is U937, KG1a, Jurkat, K562 and Namalwa cells, middle expression of beta-catenin was observed in HEL, HUT78, Raji, Daudi and CEM cells, lower expression of beta-catenin was observed in LCL-H, HL-60, NB4, J6-1 and Ramos cells.

[The analysis of prognostic variables in 123 patients with multiple myeloma].

Objective: To assess the prognostic value of biological features and therapy-related factors in multiple myeloma (MM).

Methods: 123 patients with newly diagnosed MM between January 1998 and May 2005 were enrolled in this retrospective study. Biological features at presentation and therapy-related factors were analysed.

[Cytogenetic characteristics of patients with multiple myeloma in China: analysis of 100 case].

Objective: To summarize the cytogenetic characteristics of patients with multiple myeloma (MM) in China and clinical significance thereof.

Methods: Specimens of bone marrow were collected from 100 patients with MM who visited the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences in Tianjin, China. Chromosome banding analysis and fluorescence in situ hybridization (FISH) were conducted.

[The outcome analysis of different treatment regimens in 206 patients with multiple myeloma].

Objective: To analyse the outcome of different regimens for the treatment of patients with multiple myeloma (MM).

Methods: Response rate, median survival time and overall survival rate of 206 MM patients treated with different protocols were retrospectively analysed.

Result: The median survival time, 3- and 5-year overall survival (OS) of 200 MM patients treated with conventional therapy were 30.

[The expression of CD133 in acute leukemia and its clinical significance].

Objective: To evaluate the expression of CD133 and its clinical significance in acute leukemia (AL) patients.

Methods: The expression of CD133 and CD133 mRNA in leukemic blasts from 76 AL patients were detected by three-color flow-cytometry and hemi-quantitative RT-PCR respectively.

Results: (1) CD133 mRNA expression was highly correlated with CD133 expression in both of normal donors and AL patients groups.

[Preliminary study on extensive amplification of human dendritic cells differentiated from cord blood CD34+ progenitor cells by two-step culture].

Objective: To Explore a two-step culture system to generate a large number of dendritic cells (DC) differentiated from cord blood (CB) CD(34)(+) cells.

Methods: Enriched CB CD(34)(+) cells with immunoadsorption were primarily cultured in the presence of stem cell factor (SCF), Flt-3 ligand (FL), thrombopoietin (Tpo) and interleukin-3 (IL-3) for 7 (group I), 10 (group II) or 14 days (group III) respectively, and then further cultured with GM-CSF, IL-4 and TNF-alpha for 5 - 8 days to induce DC. The expansion and cell function were evaluated by flow cytometry (FCM) and mix-lymphocyte reaction (MLR), and detection of IL-12 in the supernatant by using ELISA.